Key facts
- Notable investors include Dalton Venture, Yijing Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Super Vision (Ophthalmology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Super Vision (Ophthalmology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Super Vision (Ophthalmology)
Operator of ophthalmologic hospitals intended to provide vision healthcare. The company's hospitals provide femtosecond laser myopia treatment surgery, lens implantation, children's myopia treatment, dry eye disease treatment and other ophthalmic medical services, enabling patients maintain vision health.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Website
- jinshi0755.com/
- Ownership
- Privately Held (backing)
Super Vision (Ophthalmology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Super Vision (Ophthalmology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Super Vision (Ophthalmology) in its N-PORT filings yet. We sweep new filings monthly.